Health Trials

Spanish Series of Patients Treated With the Radionuclide Lutetium177

ConditionsNeuroendocrine TumorsIntestinal NeoplasmsPancreatic NeoplasmsStomach NeoplasmsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesGastrointestinal DiseaseIntestinal DiseasesPancreatic DiseaseEndocrine System Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorSociedad Española de Medicina Nuclear e Imagen Molecular

About this trial

This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

Eligibility criteria

Qualifiers

Written informed consent must be obtained prior to any data collection.

Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour

Aged ≥18 years.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Lutetium [177Lu] oxodotreotide/dotatate
  • Lutetium [177Lu] oxodotreotide/dotatate

Treatment groups

5,000 Participants
are divided into 1 treatment group

Locations

20
Hospital Clínico Universitario de Santiago15706, Santiago de CompostelaA Coruña, Spain
Hospital Universitario Virgen de las Nieves18014, GranadaAndalusia, Spain
Hospital Unviersitari Son Espases07120, Palma de MallorcaBalearic Islands, Spain
Hospital Universitari de Bellvitge08907, L'Hospitalet de LlobregatBarcelona, Spain

Sponsors and collaborators

Sociedad Española de Medicina Nuclear e Imagen Molecular

Lead sponsor

Source ClinicalTrials.gov